When Emma was diagnosed with triple-negative breast cancer, she didn't let it define her. There are so many ways cancer steals possibility, but at Gilead, we’re helping take it back.
At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them most. In our latest episode of The Centrifuge Sessions, Magdeleine Hung, Director of Protein Therapeutics, shares insights on our pioneering work in HIV.
GileadNews: We’re joining with Kite Pharma to announce the presentation of transformative cancer research at this year’s American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings.
We’re proud to share that “The Adventure Jar,” a children’s book supporting families impacted by metastatic breast cancer (MBC), has received two 2025 Bronze Anvil Awards from the Public Relations Society of America (PRSA).
“Living with primary biliary cholangitis (PBC) can be an isolating experience,” explains Dilek, a mother of two from Germany who suffers from the rare chronic liver disease.
Creating a healthier world for all starts with taking care of the one we all share. As one of America's Greenest Companies, we're always working to ensure our medicines are delivered in ways that safeguard the planet.
At Gilead, we innovate for impact. This commitment helps us drive scientific solutions forward, reach more people in more places and protect the planet we all share.
Congratulations to our very own Tomas Cihlar, Senior Vice President of Research, Virology, for being named to TIME's list of the 100 Most Influential People in the World.
Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch AIDSVu – an online mapping tool that visualizes granular data
At Gilead, we set and achieve bold ambitions in our fight against the world’s most devastating diseases. In this installment of The Centrifuge Sessions, See Phan, Vice President, Oncology Clinical Development
Lead PURPOSE researcher Moupali Das, Vice President, Clinical Development, HIV Prevention & Pediatrics, designed the PURPOSE program with Gilead’s person-centric approach in mind to reach underserved communities and groups around the world.
Lauren Huffmaster received a late-stage metastatic breast cancer (mBC) diagnosis in 2015 and soon discovered there wasn’t a lot information to help explain to her young children what she was going through.
Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of people around the world living with HIV.
Each scientific discovery gets us one step closer to our shared goal of ending the HIV epidemic. As a leader in HIV treatment and prevention, we’ll continue to build on our legacy and create innovative solutions to address the diverse needs of all people affected by HIV.
Maria underwent many more medical tests until a fibroscan conducted in 2018 by a hepatologist revealed that she had a rare autoimmune liver disease called primary biliary cholangitis, or PBC.
Gilead Sciences, Inc. and the Elton John AIDS Foundation announced a five-year extension of the RADIAN ® partnership to help meet the needs of the most vulnerable key populations in Eastern Europe and Central Asia (EECA) where the HIV epidemic is growing.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...